ImmunityBio Inc.
A clinical-stage immunotherapy biotechnology company focused on peptide-based immunomodulators
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ImmunityBio's stock with a target price of $7, indicating potential growth.
Financial Health
ImmunityBio is generating strong revenue and profits, with healthy cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IBRX
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical read-outs and regulatory milestones can move the share price significantly, though outcomes are binary and uncertain.
Platform Technology
Viral-vector and cytokine-based approaches aim to enhance immune response; technological promise requires clinical validation.
Funding & Partnerships
Collaborations and capital raises affect runway and commercial prospects, but financing can dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
